شراء
$GNCA UP PREMARKET ON POSITIVE CANCER VACCINE DATA
****COULD BE A GREAT MOVE IN THE DAYS TO SOME, AFTER VERY POSITIVE DATA FOR THEIR GEN-009 CANCER VACCINE******
Joseph Pantginis also upgraded the stock to $42 today, he states,
“Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our price target to $42 from $5.75. The factors impacting our target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count subsequent to the 8 reverse split.”
COMPANY PROFILE
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine.
Joseph Pantginis also upgraded the stock to $42 today, he states,
“Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our price target to $42 from $5.75. The factors impacting our target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count subsequent to the 8 reverse split.”
COMPANY PROFILE
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.